Unless we counter antibiotic resistance, we risk losing major healthcare advances
Last month, the Centres for Disease Control and Prevention (CDC), the United States’ federal agency for public health, published a report on the mounting threat of antibiotic resistance. The report, “Antibiotic Resistance Threats in the United States 2013”, listed and ranked major antibiotic-resistant organisms by their incidence, burden of disease and cost to the healthcare system.
Antibiotic resistance is the phenomenon in which a disease-causing micro-organism, usually a bacterial species, is able to survive after exposure to one or more antibiotic treatments. Microbes, not people, are resistant to antibiotics. A patient infected with an antibiotic-resistant strain of bacteria does not respond to antibiotic therapy and may die as a result of sepsis or other complications resulting from the infection. The CDC report estimates that about 23,000 patients die each year from antibiotic-resistant infections in the US alone. “If we are not careful, we will soon be in a post-antibiotic era,” Tom Frieden, the CDC’s director, said in a media briefing, emphasising that our commonly used antibiotic medications may soon cease to work against diseases. He added, “And for some patients and for some microbes, we are already there.”
Though the report primarily concerns itself with antibiotic resistance in the US, the problem is global. For example, over the last decade, tuberculosis has become impossible to treat for millions of patients infected with multiple drug-resistant strains (MDR-TB). India, China, and Russia are most affected by MDR-TB cases. Drug resistance arises from improper use or overuse of antibiotics, which is very common in many parts of the world, such as South Asia. Antibiotic resistance is primarily found in hospital-acquired infections.
India has a particularly large burden of antibiotic-resistant strains of microbes, so-called “super-bugs”, due to the overuse of antibiotic therapy, the non-regulated sale of antibiotics over the counter and the fact that most patients do not complete the full dose of the therapy. There is evidence of excessive antibiotic use in India from a survey published by the Centre for Disease Dynamics, Economics and Policy. It found that Indian pharmacy sales of carbapenems (an antibiotic used against serious hospital infections) increased by nearly six times between 2005 and 2010. A new superbug was found in India in 2010 and called New Delhi Metallo-B-Lactamase-1 (NDM-1). This naming caused great consternation and controversy. The most alarming feature of this superbug was that unlike most drug-resistant bacteria, which